{"url":"https://newsforagent.com/news/2026-11-16/adicon-crown-bioscience-deal-terminated","markdown_url":"https://newsforagent.com/news/2026-11-16/adicon-crown-bioscience-deal-terminated.md","title":"Adicon Ends Crown Bioscience Deal After Approval Delay","headline":"Adicon and Seller Terminate Crown Bioscience Purchase as Regulatory Approvals Miss Deadline","description":"Adicon Holdings terminated its $204 million purchase of Crown Bioscience after regulatory approvals missed an extended deadline.","section":"Mergers & Acquisitions","published_at":"2026-11-16T00:59:53+00:00","modified_at":"2026-11-16T00:59:53+00:00","author":"News Desk","key_takeaways":["Adicon Holdings and the seller mutually terminated the Crown Bioscience share purchase agreement effective November 13, 2026.","The deal, agreed in November 2025, would have transferred Crown Bioscience from JSR Life Sciences to Adicon for US$204 million.","Adicon's board expects no material adverse impact on the group's business operations or financial position."],"companies":[{"name":"Crown Bioscience","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0003x3f/crown-bioscience","website":"http://www.crownbio.com"}],"source":{"publisher":"The future of trading","title":"Adicon Terminates Crown Bioscience Acquisition After Regulatory Approvals Fail to Materialize","url":"https://capital.com/en-int/news/adicon-terminates-crown-bioscience-acquisition-after-regulatory-approvals-fail-to"},"other_sources":[{"publisher":"FinancialContent Business Page","url":"https://www.financialcontent.com/article/bizwire-2026-11-13-a-cap-provides-update-on-ongoing-discussions-with-palmetto-heritage-and-comments-on-recent-am-best-ratings-action"},{"publisher":"Simply Wall St","url":"https://simplywall.st/stocks/us/commercial-services/nasdaq-wldn/willdan-group/news/willdan-group-wldn-stock-looks-fully-priced-on-its-285-milli"}],"tags":["Mergers & Acquisitions","Crown Bioscience"],"body_markdown":"Adicon Holdings terminated its planned purchase of 100% of Crown Bioscience International after regulatory approvals were not obtained by an extended deadline, ending a deal agreed at US$204 million. [The future of trading](https://capital.com/en-int/news/adicon-terminates-crown-bioscience-acquisition-after-regulatory-approvals-fail-to) reported the termination on November 16, 2026.\n\n## Adicon and Seller End the Crown Bioscience Agreement\n\nAdicon Holdings and the seller mutually terminated the share purchase agreement effective November 13, 2026. The termination followed the failure to secure regulatory approvals by the extended deadline, according to the report.\n\nThe agreement had been struck in November 2025, when JSR Life Sciences entered a definitive agreement to transfer [Crown Bioscience](https://akta.pro/company-profiles/0003x3f/crown-bioscience) to Adicon Holdings Limited, an entity affiliated with The Carlyle Group, for US$204 million, with closing scheduled for 2026, according to akta.pro [company records](https://akta.pro/company-data).\n\nCrown Bioscience is a global contract research organization headquartered in San Diego that provides preclinical and translational oncology services to pharmaceutical and biotechnology companies. The company was founded in 2006 and its records list a headcount range of 1,001 to 5,000.\n\nAdicon's board expects no material adverse impact on the group's business operations or financial position from the termination.\n\n## Crown Bioscience's Research Platform and Partnerships\n\nThe same records describe Crown Bioscience's global PDX model database of 2,500+ patient-derived xenograft models, which it calls the world's largest commercial PDX collection. Its organoid models database using HUB protocols includes over 600 specialized in vitro models with associated PDXO data, and 500+ matched PDXO-PDX models span 22 cancer types.\n\nCrown Bioscience and Turbine formed a strategic partnership in April 2026 to integrate Turbine's AI-driven in silico Virtual Assays with Crown's tumor organoid assays based on HUB Organoid Technology. In September 2025, Medicines Discovery Catapult and Crown Bioscience formed a strategic global alliance for radiopharmaceutical innovation.\n\n## Other Deals in the Sector\n\n[A-CAP](https://www.financialcontent.com/article/bizwire-2026-11-13-a-cap-provides-update-on-ongoing-discussions-with-palmetto-heritage-and-comments-on-recent-am-best-ratings-action) said on November 13, 2026 that it remained in discussions with Palmetto Heritage over a potential acquisition of Atlantic Coast Life and Southern Atlantic, and that it disagreed with AM Best's downgrades.\n\n[Willdan Group](https://simplywall.st/stocks/us/commercial-services/nasdaq-wldn/willdan-group/news/willdan-group-wldn-stock-looks-fully-priced-on-its-285-milli) completed a $285 million acquisition of Mantis Innovation, a deal reported on November 12, 2026 that expands its energy efficiency platform.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}